← Patent-cliff monitor small molecule RETEVMO SELPERCATINIB
Loss of exclusivity April 2039 latest FDA-listed patent expiry
Company ELI LILLY AND CO
Drug detail Brand name RETEVMO Active ingredient SELPERCATINIB Strength 40MG Dosage form CAPSULE Route ORAL Modality Small molecule FDA approval May 2020 Marketing status RX
Listed patents Patent Expires Type 10584124*PED April 2039 — 12138250*PED April 2039 — 10786489*PED April 2039 — 12138250 October 2038 use U-3450 10584124 October 2038 substance 10786489 October 2038 product 10137124*PED April 2038 — 10172851*PED April 2038 — 10112942*PED April 2038 — 10137124 October 2037 use U-3951 10112942 October 2037 substance, product 10172851 October 2037 use U-3951
Regulatory exclusivity Code Expires PED November 2031 ODE-484 May 2031 ODE-487 May 2031 ODE-485 May 2031 PED March 2030 ODE-409 September 2029 ODE-412 September 2029 PED March 2028 PED November 2027 PED November 2027 M-312 September 2027 M-311 September 2027 NPP May 2027 ODE-301 May 2027 ODE-302 May 2027 ODE-303 May 2027
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.